European Committee for Treatment and Research in Mulitple Sclerosis 2019
The 35th Congress of the European Committee for Treatment and Research in Mulitple Sclerosis (ECTRIMS) was held in Stockholm, Sweden, from September 11 to 13, 2019. The congress covered all the latest and exciting new developments in multiple sclerosis, including treatment, genetics, pathology, imaging, immunology, and epidemiology.
The neurologist at the National MS Center and University Hospital, in Brussels, discussed the clinician mindset when treating women with MS who plan to get pregnant, and how patients using assistive reproductive treatments should be approached.
The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.
The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet discussed the evolving understanding of the blood-brain barrier in MS, and what might still be left to uncover.
Mallinckrodt’s repository corticotropin injection was shown to have a lower cost per patient response compared to other late-line treatments for multiple sclerosis relapses, costing an estimated $148,528 less per response.
The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the aspects of MS—such as brain volume loss—which are not currently being addressed by the available disease-modifying therapies.
According to new data from STRIVE, 75.4% of those treated with natalizumab achieved overall No Evidence of Disease Activity status by year 4, and no patients had incidence of progressive multifocal leukoencephalopathy.
The global head of neuroimmunology at Genentech spoke about the wealth of data being presented on its anti-CD20 monoclonal antibody ocrelizumab, as well as the success thus far in trials of its NMOSD agent, satralizumab.
The professor of epidemiology and nutrition at Harvard TH Chan School of Public Health discussed what might be an optimal dose of vitamin D supplementation in MS, and how vitamin D deficiency should be addressed as a modifiable risk factor.
New phase 3 data from the OPTIMUM head-to-head trial show that 20-mg ponesimod resulted in a significantly lower annualized relapse rate in adults with multiple sclerosis compared to 14-mg teriflunomide at 108 weeks.
New decade-long data have suggested that multiple sclerosis treatment with dimethyl fumarate is associated with stable EDSS scores ≤3, and a low number of patients with confirmed disability progression.
Data from the phase 3 SUNBEAM trial of the sphingosine 1-phosphate receptor modulator have suggested that the Celgene treatment lowers annualized relapse rates and reduces the rate of cortical gray matter loss, improving cognition measures, compared to IFN-ß1a.